Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10809636
Filing Date		2004-03-24
First Named Inventor Jun F		ENG
Art Unit		1624
Examiner Name	Kahs	ay Habte
Attorney Docket Number		DPP4-5004-C1

U.S.PATENTS Remove											
Examiner Cite   Patent Number   Kind   Issue Date   Name of Patentee or A   Of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear								
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	1	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document Pages, Column Relevant Pass Figures Appea		nt Passa	ges or Relev		
	1										
If you wis	h to a	dd additional U.S. Publi		,				d button			
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Applicant of cited Where		vhere Re	or Relevant	+=
	1	EP 900568 A2	EP			2004-03-10	Chenard et al.				С
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	-PATEN	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs					

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

pplication Number		10809636
iling Date		2004-03-24
irst Named Inventor Jun F		ENG
rt Unit		1624
xaminer Name Kahs		ay Hable
ttorney Docket Number		DPP4-5004-C1

	1	Chenard et al. J. Med Chem. 2001, 44, 1710-1717				
	2	An abstract of Pattansik et al. Indian Journal of Chemistry, Section B; Organic Chemistry including Medicinal Chemistry (1989), 378 (12), 1304-1306 from STN CAS online search printout (3 pages).				
	3	Abstract of EP 900568 A2 from STN CAS online search printlout (3 pages).				
	4	Kozhevnikov et al. Tr. Perm. Sel-Khoz. Inst. (1971), No. 79, 66-72 From ref. Zh., Khim. 1972, Abst. No. 9Zh404 Cuurnal (English Abstract attached).				
	5	Somaseichara et al. Indian Journal of Pharmacey (1972), 34(5), 121-2.				
If you wish to add additional non-patent literature document citation information please click the Add button Add						
		EXAMINER SIGNATURE				
Evaminar	Ciana	Data Considered				

A

E

1 See Kinz Codes of USPTO Patent Documents at year USPTO\_CODE or MIPEP 801.64. <sup>2</sup> Enter office that issued the document, by the ho-letter code (WIPO Standard ST.3.) <sup>2</sup> or Juranees patent concurrent, by manufactor of the year of the Empore many protective be seen all number of the patent document, by the option columents, be made along the year of the Empore many protective be seen all number of the patent document, and the patent document, and the patent document with the patent of the patent protection of the patent patent document with the patent paten

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10809636
Filing Date		2004-03-24
First Named Inventor Jun F		ENG
Art Unit		1624
Examiner Name	Kahs	ay Hable
Attorney Docket Number		DPP4-5004-C1

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement, See 37 CFR 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement, was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

_	C	-4

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mrtchell R. Brustein/	Date (YYYY-MM-DD)	2006-08-16						
Name/Drint	Mitchell P. Brustein	Registration Number	38 304						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.